Search Page

1

Cite

Share

Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.

Gross RH, Corboy JR. Gross RH, et al. Continuum (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738. Continuum (Minneap Minn). 2019. PMID: 31162313 Review.

Cite

Share

2

Cite

Share

Pregnancy and Family Planning in Multiple Sclerosis.

Langer-Gould AM. Langer-Gould AM. Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745. Continuum (Minneap Minn). 2019. PMID: 31162316 Review.

Cite

Share

3

Cite

Share

Aseptic meningitis after glatiramer acetate.

Niessen A, Schwarz B, Urban M, Krämer S, Reinhard M. Niessen A, et al. J Neurol. 2021 Jul;268(7):2589-2590. doi: 10.1007/s00415-021-10572-z. Epub 2021 Apr 28. J Neurol. 2021. PMID: 33909159 No abstract available.

Cite

Share

4

Cite

Share

Glatiramer acetate attenuates renal ischemia reperfusion injury in rat model.

Nezamoleslami S, Sheibani M, Dehpour AR, Mobasheran P, Shafaroodi H. Nezamoleslami S, et al. Exp Mol Pathol. 2020 Feb;112:104329. doi: 10.1016/j.yexmp.2019.104329. Epub 2019 Nov 4. Exp Mol Pathol. 2020. PMID: 31697931

Cite

Share

5

Cite

Share

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate.

Erzina D, Capecchi A, Javor S, Reymond JL. Erzina D, et al. Angew Chem Int Ed Engl. 2021 Dec 6;60(50):26403-26408. doi: 10.1002/anie.202113562. Epub 2021 Nov 5. Angew Chem Int Ed Engl. 2021. PMID: 34618395 Free PMC article.

Cite

Share

6

Cite

Share

Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.

Bovis F, Kalincik T, Lublin F, Cutter G, Malpas C, Horakova D, Havrdova EK, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Izquierdo G, Eichau S, Patti F, Terzi M, Grammond P, Bergamaschi R, Sola P, Ferraro D, Ozakbas S, Iuliano G, Boz C, Hupperts R, Grand'Maison F, Oreja-Guevara C, van Pesch V, Cartechini E, Petersen T, Altintas A, Soysal A, Ramo-Tello C, McCombe P, Turkoglu R, Butzkueven H, Wolinsky JS, Solaro C, Sormani MP. Bovis F, et al. Neurology. 2021 Jan 12;96(2):e214-e227. doi: 10.1212/WNL.0000000000010991. Epub 2020 Oct 6. Neurology. 2021. PMID: 33024022 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.

Landmeyer NC, Bürkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, Meuth SG, Johnen A. Landmeyer NC, et al. Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522. Epub 2020 May 19. Neurology. 2020. PMID: 32430312

Cite

Share

8

Cite

Share

Glatiramer acetate during early pregnancy: A prospective cohort study.

Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K. Herbstritt S, et al. Mult Scler. 2016 May;22(6):810-6. doi: 10.1177/1352458515623366. Epub 2016 Jan 11. Mult Scler. 2016. PMID: 26754804

Cite

Share

9

Cite

Share

Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.

McKeage K. McKeage K. CNS Drugs. 2015 May;29(5):425-32. doi: 10.1007/s40263-015-0245-z. CNS Drugs. 2015. PMID: 25906331 Review.

Cite

Share

10

Cite

Share

Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology.

Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M. Baruch K, et al. Nat Commun. 2015 Aug 18;6:7967. doi: 10.1038/ncomms8967. Nat Commun. 2015. PMID: 26284939 Free PMC article.

Cite

Share